mbs303MBS 303 is a bispecific antibody targeting CD3CD20 being developed by Beijing Mabworks Biotech for the treatment of B cell non-Hodgkin lymphoma. TheMBS303MSC303 (MBS303 as the intravenous formulation, MSC303 as the subcutaneous formulation) is an innovative CD20CD3 T-cell engager. MBS303 has initiated clinical trials